Zimmer Biomet (ZBH) is well-poised to grow in the coming quarters owing to the encouraging business recovery and increased provider capacity driving backlog pull-through. The company also progresses on the four-pillar strategy to expand the Knee business. Further, the global musculoskeletal market’s gradual stabilization bodes well for its operations. Meanwhile, unfavorable solvency and currency fluctuations raise concerns for Zimmer Biomet. In the past year, this Zacks Rank #3 (Hold) stock has declined 11% ...